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Abstract
Background: Harmaline-induced tremor in rodents has been extensively used as an animal model for essential tremor (ET). However, there is no visual
documentation in the published literature.
Methods: We injected mice subcutaneously with either 20 mg/kg of harmaline hydrochloride or saline and then videotaped the responses.
Results: Action and postural tremor in the mouse began 5 minutes after subcutaneous harmaline injection and peaked at approximately 30 minutes. The tremor
involved the head, trunk, tail, and four limbs and lasted for approximately 2 hours. The forelimb tremor was postural or action tremor, similar to that observed in
ET.
Discussion: This video segment provides the first visual documentation of the phenomenology of harmaline-induced tremor in a mouse. We also raise several
unanswered questions regarding the use of harmaline-induced tremor to model ET.
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Introduction
Essential tremor (ET) is the most common type of tremor,
characterized by action and postural tremor in the upper extremities
and/or neck and voice tremor.1 The underlying mechanisms of ET
have been extensively investigated. Genetic factors are important in
ET, as it is common in kindreds.2 However, the concordance in
monozygotic twins is only about 60–63%,3 indicating that environ-
mental factors also play a role in ET.4
b-carboline alkaloids (BCAs), including norharman, harmane, harmine,
harmaline, and ibogaine, are well known to induce action and postural
tremor in mice, rats, rabbits, cats, and monkeys.5–9 Exposure to exogenous
BCAs seems to be associated with ET, as ET patients have higher levels of
harmane in the blood and brain as compared to healthy controls.10–15
Harmaline can induce tremor by the mechanism of synchronized firing in
the inferior olivary nucleus (IO), leading to rhythmic activity within the
olivocerebellar system, which has been hypothesized by some to be the
anatomical substrate of ET.16 Harmaline-induced tremor in animals is
predominantly postural and action at the frequency of 8–14 Hz, similar to
tremor in ET patients.17,18 Furthermore, treatments for ET, such as b-
blockers and primidone, can dampen harmaline-induced tremor.18 These
findings suggest that harmaline-induced rodent tremor models might be
useful to investigate the mechanisms of ET.
Despite extensive research on harmaline-induced tremor in rodents,
visual documentation of this tremor in published literature is lacking.
The goal of the current study was to 1) provide video of harmaline-
induced tremor in a mouse, 2) describe in detail the phenomenology of
harmaline-induced tremor, 3) raise several unanswered questions
regarding the use of harmaline-induced tremor to model ET.
Methods
We subcutaneously injected C57/BL6 mice with either harmaline
20 mg/kg or saline and observed tremor at rest, posture, and action.
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Results
Five minutes after subcutaneous harmaline administration, we
observed tremors at approximately 10–16 Hz, involving the head,
trunk, and tail (Video). The tremor became more apparent during
locomotion and occurred only intermittently at rest. The tremor lasted
for approximately 2 hours. A head tremor was noted on elevating the
head and was mainly seen as a vertical motion. The tail tremor was
also mostly vertical. The forelimb tremor was seen when the animal
reared and raised its forepaw. The hindlimbs also had tremor during
locomotion. Control mice did not have any apparent tremors (Video).
In addition, harmaline also caused slow locomotion, but these
symptoms disappeared when the tremor resolved.
Discussion
We present the first visual documentation of harmaline-induced
tremor in mice. We observed postural and action tremors, as
previously reported.8,17 In addition, we observed prominent forelimb
postural tremors in harmaline-treated mice, which have not been
described in detail.
Acute harmaline-induced tremors in rodents are a very useful
animal model for ET research as they recapitulate disease phenotypes,
and this report further supports this notion. Acute harmaline or
ibogaine exposure in rats can also induce cerebellar Purkinje cell (PC)
loss,8,20 which is a major pathological feature of ET pathology.21,22
Harmaline and other BCAs can cause synchronization of rhythms in
the IO and climbing fibers, which subsequently leads to PC
dysfunction. ET, along with action tremors due to other causes, such
as post-traumatic tremor, tremor of hyperthyroidism, and valproate-
induced tremor, may share common anatomical tremor circuits with
harmaline-induced tremor, and thus have similar pharmacological
responses to treatment.19 We observed mild unsteadiness in a
harmaline-treated mouse during the period of tremor. However,
whether harmaline can cause ataxic gait in mice requires further
investigation. In addition, harmaline-treated mice also exhibited slow
movements and locomotion, but these resolved with the resolution of
tremor and were likely a secondary response to the tremor rather than
bradykinesia per se. Thus, it is more likely that slowness is an aversive
response to action and postural tremor17 rather than a direct effect of
harmaline on the basal ganglia.
There are several unanswered questions with regard to the use of
harmaline-induced tremor to model ET. First, several postmortem
studies found structural changes in the cerebellum, such as PC axonal
torpedoes22 and other associated axonal pathology,23 basket cell
axonal process changes,24,25 and heterotopic PCs.26 Acute effects of
harmaline are unlikely to recapitulate these chronic pathological
features of ET, although this remains to be determined. Second, the
chronic effects of harmaline in terms of tremor characteristics and
duration are poorly understood. Chronic administration of harmaline
or other BCAs might be more useful in studying ET, especially for
screening treatments that could prevent or reverse the pathological
features of ET. The chronic effects of harmaline in mice have not been
extensively investigated, and establishing a chronic harmaline tremor
mouse model might be an important future research direction.
References
1. Louis ED. Clinical practice. Essential tremor. N Engl J Med 2001;345:887–
891, doi: http://dx.doi.org/10.1056/NEJMcp010928.
2. Deng H, Le W, Jankovic J. Genetics of essential tremor. Brain 2007;130:
1456–1464, doi: http://dx.doi.org/10.1093/brain/awm018.
3. Tanner CM, Goldman SM, Lyons KE, et al. Essential tremor in twins: an
assessment of genetic vs environmental determinants of etiology. Neurology 2001;
57:1389–1391, doi: http://dx.doi.org/10.1212/WNL.57.8.1389.
4. Louis ED. Environmental epidemiology of essential tremor.
Neuroepidemiology 2008;31:139–149, doi: http://dx.doi.org/10.1159/000151523.
5. Du W, Aloyo VJ, Harvey JA. Harmaline competitively inhibits [3H]MK-
801 binding to the NMDA receptor in rabbit brain. Brain Res 1997;770:26–29,
doi: http://dx.doi.org/10.1016/S0006-8993(97)00606-9.
6. De Montigny C, Lamarre Y. Effects produced by local applications of
harmaline in the inferior olive. Can J Physiol Pharmacol 1975;53:845–849, doi:
http://dx.doi.org/10.1139/y75-116.
7. Bergstro¨m M, Westerberg G, Kihlberg T, La˚ngstro¨m B. Synthesis of some
11C-labelled MAO-A inhibitors and their in vivo uptake kinetics in rhesus
monkey brain. Nucl Med Biol 1997;24:381–388.
8. Miwa H, Kubo T, Suzuki A, Kihira T, Kondo T. A species-specific
difference in the effects of harmaline on the rodent olivocerebellar system. Brain
Res 2006;1068:94–101, doi: http://dx.doi.org/10.1016/j.brainres.2005.11.036.
9. Zetler G, Singbartl G, Schlosser L. Cerebral pharmacokinetics of tremor-
producing harmala and iboga alkaloids. Pharmacology 1972;7:237–248, doi:
http://dx.doi.org/10.1159/000136294.
10. Louis ED, Benito-Leo´n J, Moreno-Garcı´a S, et al. Blood harmane (1-
methyl-9H-pyrido[3,4-b]indole) concentration in essential tremor cases in
Video 1. Harmaline-induced Tremor. Subcutaneous administration of
20 mg/kg harmaline induced whole-body tremor in a mouse, whereas the saline-
injected control mouse had no tremor. The harmaline-treated mouse exhibited
action tremor in the body and tail during locomotion, as well as forelimb postural
and action tremor. The harmaline-treated mouse also had intermittent rest
tremor. The control mouse did not have any action tremor or forelimb tremors.
Cheng MMH, Tang GM, Kuo SH Harmaline-induced Tremor in Mice
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services2
Spain. Neurotoxicology 2013;34:264–268, doi: http://dx.doi.org/10.1016/j.
neuro.2012.09.004.
11. Louis ED, Zheng W, Applegate L, Shi L, Factor-Litvak P. Blood
harmane concentrations and dietary protein consumption in essential tremor.
Neurology 2005;65:391–396, doi: http://dx.doi.org/10.1212/01.wnl.
0000172352.88359.2d.
12. Louis ED, Jiang W, Pellegrino KM, et al. Elevated blood harmane (1-
methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremor. Neurotoxicology
2008;29:294–300, doi: http://dx.doi.org/10.1016/j.neuro.2007.12.001.
13. Louis ED, Factor-Litvak P, Liu X, et al. Elevated brain harmane (1-methyl-
9H-pyrido[3,4-b]indole) in essential tremor cases vs. controls. Neurotoxicology 2013;
38:131–135, doi: http://dx.doi.org/10.1016/j.neuro.2013.07.002.
14. Louis ED, Zheng W, Jurewicz EC, et al. Elevation of blood beta-
carboline alkaloids in essential tremor. Neurology 2002;59:1940–1944, doi:
http://dx.doi.org/10.1212/01.WNL.0000038385.60538.19.
15. Louis ED, Rios E, Pellegrino KM, et al. Higher blood harmane (1-
methyl-9H-pyrido[3,4-b]indole) concentrations correlate with lower olfactory
scores in essential tremor. Neurotoxicology 2008;29:460–465, doi: http://dx.doi.
org/10.1016/j.neuro.2008.02.013.
16. Llina´s R, Yarom Y. Oscillatory properties of guinea-pig inferior olivary
neurones and their pharmacological modulation: an in vitro study. J. Physiol
1986;376:163–182.
17. Miwa H. Rodent models of tremor. Cerebellum 2007;6:66–72, doi: http://
dx.doi.org/10.1080/14734220601016080.
18. Martin FC, Thu Le A, Handforth A. Harmaline-induced tremor as a
potential preclinical screening method for essential tremor medications. Mov
Disord 2005;20:298–305, doi: http://dx.doi.org/10.1002/mds.20331.
19. Elble RJ. Tremor disorders. Curr Opin Neurol 2013;26:413–419, doi:
http://dx.doi.org/10.1097/WCO.0b013e3283632f46.
20. O’Hearn E, Molliver ME. The olivocerebellar projection mediates
ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-
synaptic excitotoxicity. J Neurosci 1997;17:8828–8841.
21. Axelrad JE, Louis ED, Honig LS, et al. Reduced Purkinje cell number in
essential tremor: a postmortem study. Arch Neurol 2008;65:101–107, doi: http://
dx.doi.org/10.1001/archneurol.2007.8.
22. Louis ED, Faust PLP, Vonsattel JP, et al. Neuropathological changes in
essential tremor: 33 cases compared with 21 controls. Brain 2007;130:3297–
3307, doi: http://dx.doi.org/10.1093/brain/awm266.
23. Babij R, Lee M, Cortes E, et al. Purkinje cell axonal anatomy:
quantifying morphometric changes in essential tremor versus control brains.
Brain 2013;136:3051–3061, doi: http://dx.doi.org/10.1093/brain/awt238.
24. Erickson-Davis CR, Faust PL, Vonsattel JP, Gupta S, Honig LS, Louis
ED. ‘‘Hairy baskets’’ associated with degenerative Purkinje cell changes in
essential tremor. J Neuropathol Exp Neurol 2010;69:262–271, doi: http://dx.doi.
org/10.1097/NEN.0b013e3181d1ad04.
25. Kuo SH, Tang G, Louis ED, et al. Lingo-1 expression is increased in
essential tremor cerebellum and is present in the basket cell pinceau. Acta
Neuropathol 2013;125:879–889, doi: http://dx.doi.org/10.1007/s00401-013-
1108-7.
26. Kuo SH, Erickson-Davis C, Gillman A, Faust PL, Vonsattel JP, Louis
ED. Increased number of heterotopic Purkinje cells in essential tremor. J Neurol
Neurosurg Psychiatry 2011;82:1038–1040, doi: http://dx.doi.org/10.1136/jnnp.
2010.213330.
Harmaline-induced Tremor in Mice Cheng MMH, Tang GM, Kuo SH
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services3
